September 25, 2018
MONALEESA-3 Data Highlight Ribociclib as Standard in HR+ Breast Cancer BookmarkEmma Shtivelman, PhD
Excerpt from OncLive:
“Findings from the MONALEESA-3 trial dispelled the theory that a CDK4/6 inhibitor had to be reserved following recurrence on hormone therapy in postmenopausal patients with hormone receptor (HR)-positive, HER2-negative breast cancer, explained Dennis J. Slamon, MD, PhD.
“In the phase III trial, postmenopausal patients with HR-positive, HER2-negative advanced disease who received up to 1 prior line of therapy were randomized 2:1 to ribociclib (Kisqali) plus fulvestrant (Faslodex) or placebo.”
Go to full article published by OncLive on Sep 18, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
January 17, 2017
In Metastatic Breast Cancer Treatment, Not All CDK Inhibitors Are EqualEmma Shtivelman, PhD
Doctors prescribe drugs known as CDK inhibitors to treat some women with estrogen-receptor-positive (ER+) metastatic breast cancer. Research into these drugs is ongoing, and new, promising CDK inhibitor options are on the horizon. Here, I address the current outlook for CDK inhibitors in ER+ breast cancer. First, some background: ER+ breast cancers comprise about 70% of all breast cancers. The name reflects the fact… Read more »